Institute for Experimental Pathology, Center for Molecular Biology of Inflammation, Westfälische Wilhelms-Universität, Münster, Germany.
Institute for Cardiovascular Prevention, Klinikum der Ludwig-Maximilians-Universität, Munich, Germany.
Nat Rev Drug Discov. 2021 Aug;20(8):589-610. doi: 10.1038/s41573-021-00198-1. Epub 2021 May 11.
Atherosclerosis, a dominant and growing cause of death and disability worldwide, involves inflammation from its inception to the emergence of complications. Targeting inflammatory pathways could therefore provide a promising new avenue to prevent and treat atherosclerosis. Indeed, clinical studies have now demonstrated unequivocally that modulation of inflammation can forestall the clinical complications of atherosclerosis. This progress pinpoints the need for preclinical investigations to refine strategies for combatting inflammation in the human disease. In this Review, we consider a gamut of attractive possibilities for modifying inflammation in atherosclerosis, including targeting pivotal inflammatory pathways such as the inflammasomes, inhibiting cytokines, manipulating adaptive immunity and promoting pro-resolution mechanisms. Along with lifestyle measures, pharmacological interventions to mute inflammation could complement traditional targets, such as lipids and hypertension, to make new inroads into the management of atherosclerotic risk.
动脉粥样硬化是全球范围内主要且日益增长的死亡和残疾原因，从其起始到并发症出现都涉及炎症。因此，靶向炎症途径可能为预防和治疗动脉粥样硬化提供一个有前途的新途径。事实上，临床研究现在已经明确表明，炎症的调节可以预防动脉粥样硬化的临床并发症。这一进展明确需要进行临床前研究，以完善针对人类疾病炎症的治疗策略。在这篇综述中，我们考虑了一系列有吸引力的可能性，以改变动脉粥样硬化中的炎症，包括靶向关键的炎症途径，如炎症小体，抑制细胞因子，调节适应性免疫和促进 resolution 机制。除了生活方式措施外，抑制炎症的药物干预可能会补充传统的靶点，如脂质和高血压，为管理动脉粥样硬化风险开辟新途径。
